BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 15036041)

  • 1. CTL ontogeny and viral escape: implications for HIV-1 vaccine design.
    Yang OO
    Trends Immunol; 2004 Mar; 25(3):138-42. PubMed ID: 15036041
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccine-induced T cells control reversion of AIDS virus immune escape mutants.
    Fernandez CS; Smith MZ; Batten CJ; De Rose R; Reece JC; Rollman E; Venturi V; Davenport MP; Kent SJ
    J Virol; 2007 Apr; 81(8):4137-44. PubMed ID: 17251297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rates of HIV immune escape and reversion: implications for vaccination.
    Davenport MP; Loh L; Petravic J; Kent SJ
    Trends Microbiol; 2008 Dec; 16(12):561-6. PubMed ID: 18964018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV and SIV CTL escape: implications for vaccine design.
    Goulder PJ; Watkins DI
    Nat Rev Immunol; 2004 Aug; 4(8):630-40. PubMed ID: 15286729
    [No Abstract]   [Full Text] [Related]  

  • 5. HIV/AIDS. HLA leaves its footprints on HIV.
    McMichael A; Klenerman P
    Science; 2002 May; 296(5572):1410-1. PubMed ID: 12029119
    [No Abstract]   [Full Text] [Related]  

  • 6. Reversion of immune escape HIV variants upon transmission: insights into effective viral immunity.
    Kent SJ; Fernandez CS; Dale CJ; Davenport MP
    Trends Microbiol; 2005 Jun; 13(6):243-6. PubMed ID: 15936652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV CTL escape: at what cost?
    Smith SM
    Retrovirology; 2004 May; 1():8. PubMed ID: 15169568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial.
    Matano T; Kobayashi M; Igarashi H; Takeda A; Nakamura H; Kano M; Sugimoto C; Mori K; Iida A; Hirata T; Hasegawa M; Yuasa T; Miyazawa M; Takahashi Y; Yasunami M; Kimura A; O'Connor DH; Watkins DI; Nagai Y
    J Exp Med; 2004 Jun; 199(12):1709-18. PubMed ID: 15210746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CTL responses to HIV and SIV: wrestling with smoke.
    John M; Mallal S
    Nat Immunol; 2005 Mar; 6(3):232-4. PubMed ID: 15716970
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytotoxic T-cell epitopes in HIV/SIV infection.
    Venet A; Walker BD
    AIDS; 1993; 7 Suppl 1():S117-26. PubMed ID: 7689848
    [No Abstract]   [Full Text] [Related]  

  • 11. Humoral immunity to HIV, SIV, and SHIV.
    Haigwood NL; Zolla-Pazner S
    AIDS; 1998; 12 Suppl A():S121-32. PubMed ID: 9632993
    [No Abstract]   [Full Text] [Related]  

  • 12. Reversion of CTL escape-variant immunodeficiency viruses in vivo.
    Friedrich TC; Dodds EJ; Yant LJ; Vojnov L; Rudersdorf R; Cullen C; Evans DT; Desrosiers RC; Mothé BR; Sidney J; Sette A; Kunstman K; Wolinsky S; Piatak M; Lifson J; Hughes AL; Wilson N; O'Connor DH; Watkins DI
    Nat Med; 2004 Mar; 10(3):275-81. PubMed ID: 14966520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AIDS. Escape from the immune system.
    Walker BD; Goulder PJ
    Nature; 2000 Sep; 407(6802):313-4. PubMed ID: 11014174
    [No Abstract]   [Full Text] [Related]  

  • 14. Protection by dendritic cells-based HIV synthetic peptide cocktail vaccine: preclinical studies in the SHIV-rhesus model.
    Nehete PN; Nehete BP; Manuri P; Hill L; Palmer JL; Sastry KJ
    Vaccine; 2005 Mar; 23(17-18):2154-9. PubMed ID: 15755586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo fitness costs of different Gag CD8 T-cell escape mutant simian-human immunodeficiency viruses for macaques.
    Loh L; Batten CJ; Petravic J; Davenport MP; Kent SJ
    J Virol; 2007 May; 81(10):5418-22. PubMed ID: 17344299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AIDS vaccine models: challenging challenge viruses.
    Feinberg MB; Moore JP
    Nat Med; 2002 Mar; 8(3):207-10. PubMed ID: 11875482
    [No Abstract]   [Full Text] [Related]  

  • 18. Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques.
    Kawada M; Igarashi H; Takeda A; Tsukamoto T; Yamamoto H; Dohki S; Takiguchi M; Matano T
    J Virol; 2006 Feb; 80(4):1949-58. PubMed ID: 16439550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for AIDS virus infections: cautious optimism for cell-based vaccine.
    Bhardwaj N; Walker BD
    Nat Med; 2003 Jan; 9(1):13-4. PubMed ID: 12514710
    [No Abstract]   [Full Text] [Related]  

  • 20. HIV escape: there and back again.
    Altman JD; Feinberg MB
    Nat Med; 2004 Mar; 10(3):229-30. PubMed ID: 14991039
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.